[go: up one dir, main page]

DE60120840D1 - Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursal-Krankheit - Google Patents

Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursal-Krankheit

Info

Publication number
DE60120840D1
DE60120840D1 DE60120840T DE60120840T DE60120840D1 DE 60120840 D1 DE60120840 D1 DE 60120840D1 DE 60120840 T DE60120840 T DE 60120840T DE 60120840 T DE60120840 T DE 60120840T DE 60120840 D1 DE60120840 D1 DE 60120840D1
Authority
DE
Germany
Prior art keywords
mutants
disease virus
bursal disease
infectious bursal
vaccines based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60120840T
Other languages
English (en)
Other versions
DE60120840T2 (de
Inventor
Adriaan Antonius Wilhelmu Loon
Egbert Mundt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of DE60120840D1 publication Critical patent/DE60120840D1/de
Application granted granted Critical
Publication of DE60120840T2 publication Critical patent/DE60120840T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60120840T 2000-07-07 2001-07-02 Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursitis Expired - Lifetime DE60120840T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00202430 2000-07-07
EP00202430 2000-07-07
EP01201064 2001-03-22
EP01201064 2001-03-22

Publications (2)

Publication Number Publication Date
DE60120840D1 true DE60120840D1 (de) 2006-08-03
DE60120840T2 DE60120840T2 (de) 2006-11-16

Family

ID=26072471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120840T Expired - Lifetime DE60120840T2 (de) 2000-07-07 2001-07-02 Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursitis

Country Status (13)

Country Link
US (1) US6485940B2 (de)
JP (1) JP2002095485A (de)
KR (1) KR100759769B1 (de)
CN (1) CN1257973C (de)
AT (1) ATE330969T1 (de)
AU (1) AU780878B2 (de)
BR (1) BR0102776A (de)
CA (1) CA2351010C (de)
DE (1) DE60120840T2 (de)
HU (1) HU225488B1 (de)
MX (1) MXPA01006919A (de)
NZ (1) NZ512800A (de)
PL (1) PL199159B1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608741A2 (de) * 2003-03-24 2005-12-28 Akzo Nobel N.V. Mutanten des infektiöse-bursitis-virus und impfstoffe
US7491399B2 (en) * 2005-06-23 2009-02-17 University Of Maryland Biotechnology Institute In Ovo vaccine against infectious bursal disease
CN100384990C (zh) * 2005-11-14 2008-04-30 浙江大学 传染性法氏囊病病毒无毒力毒株构建方法
DE102006054260A1 (de) * 2006-02-28 2007-09-27 Lohmann Animal Health Gmbh & Co. Kg Wasser stabilisierende Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481072A4 (en) 1990-05-04 1993-06-09 University Of Maryland At College Park Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
WO2000012677A2 (en) 1998-09-01 2000-03-09 The University Of Hong Kong Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines

Also Published As

Publication number Publication date
AU780878B2 (en) 2005-04-21
NZ512800A (en) 2002-03-01
CN1366041A (zh) 2002-08-28
HU225488B1 (en) 2006-12-28
DE60120840T2 (de) 2006-11-16
PL199159B1 (pl) 2008-08-29
US20020064532A1 (en) 2002-05-30
CA2351010A1 (en) 2002-01-07
JP2002095485A (ja) 2002-04-02
HUP0102823A3 (en) 2005-06-28
BR0102776A (pt) 2002-07-23
AU5419601A (en) 2002-01-10
HU0102823D0 (en) 2001-09-28
CN1257973C (zh) 2006-05-31
HUP0102823A2 (hu) 2002-04-29
CA2351010C (en) 2010-12-14
ATE330969T1 (de) 2006-07-15
KR20020013387A (ko) 2002-02-20
MXPA01006919A (es) 2003-09-25
US6485940B2 (en) 2002-11-26
PL348550A1 (en) 2002-01-14
KR100759769B1 (ko) 2007-10-04

Similar Documents

Publication Publication Date Title
DK1618889T3 (da) Influenzavaccine
MXPA05009580A (es) Vacuna contra el virus de la influenza.
HRP20040195B1 (hr) Cjepivo protiv bolesti zapadnoga nila
EP1504112A4 (de) Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten
PT777490E (pt) Enterotoxina mutante eficaz como adjuvante oral nao toxico
JP2004509903A5 (de)
ATE272410T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
ATE426412T1 (de) Adjuvante influenza-vakzine
AU2481502A (en) A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
MX2022000718A (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9.
ATE416788T1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
JP2006512078A5 (de)
ATE330969T1 (de) Impfstoffe basierend auf mutanten des virus der infektiösen bursal-krankheit
DK1610817T3 (da) Infektiøs bronkitis virus med et ændret spike-gen
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
MX2007004004A (es) Vacunas multivalentes contra la influenza aviar.
ECSP14023407A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
ES2053477T3 (es) Vacuna viva para enfermedades contagiosas de pollos.
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
HUP0101652A1 (hu) Új kompozíció
RU2006118106A (ru) Вектор химерного аденовируса типа 5/типа 35
TW200710224A (en) Attenuated avian infectious bronchitis virus vaccines
AR048429A1 (es) Aislados antigenicos y vacunas del virus de la bursitis infecciosa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition